Immunocore Holdings plc (NASDAQ:IMCR) Holdings Cut by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 8.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 502,857 shares of the company's stock after selling 43,461 shares during the period. Principal Financial Group Inc. owned about 1.01% of Immunocore worth $14,835,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after buying an additional 960 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in Immunocore by 36.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock worth $1,121,000 after acquiring an additional 10,217 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Immunocore by 125.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock worth $1,463,000 after acquiring an additional 27,598 shares during the last quarter. Pier Capital LLC grew its stake in Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company's stock worth $2,568,000 after acquiring an additional 1,174 shares during the period. Finally, XTX Topco Ltd raised its holdings in Immunocore by 72.9% in the 3rd quarter. XTX Topco Ltd now owns 15,459 shares of the company's stock valued at $481,000 after acquiring an additional 6,516 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

IMCR has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Friday. Needham & Company LLC reiterated a "buy" rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday. Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $72.00 to $38.00 in a report on Monday, November 11th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 price target (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Immunocore has an average rating of "Moderate Buy" and an average price target of $65.64.

Immunocore Stock Down 0.7 %

Shares of NASDAQ:IMCR traded down $0.21 during midday trading on Friday, hitting $29.37. 181,954 shares of the company's stock traded hands, compared to its average volume of 229,183. The firm's fifty day moving average price is $30.08 and its two-hundred day moving average price is $31.85. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a twelve month low of $27.69 and a twelve month high of $72.05. The company has a market cap of $1.47 billion, a PE ratio of -30.92 and a beta of 0.77.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.